FDA approved the marketing of 23andMe’s Bloom Syndrome carrier test, a direct-to-consumer genetic test to determine whether a healthy person has a variant in a gene that could lead to their offspring inheriting the disorder.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
